Skip to main content
Equibles
ACRS logo

ACRS · Aclaris Therapeutics, Inc. · Earnings Call Transcripts & Audio

Track ACRS — free

Use ACRS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACRS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.32 -0.19 (-3.36%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$783.10M
Shares
147.20M

Aclaris Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Aclaris Therapeutics, Inc. (ACRS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼70.2% $1.09M −$18.59M '19 Q4 20-02-25 ▲74% $2.53M −$28.16M '23 Q1 23-05-08 ▼5.1% $2.40M −$16.94M '24 Q1 24-05-07 ▼85.9% $1.29M −$19.80M '25 Q4 26-01-06 LATEST ▲37.2% $2.00M −$19.82M '26 Q1 26-04-28
Conference
Investor event
2026-06-04
Aclaris Therapeutics, Inc. (ACRS) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-28
Aclaris Therapeutics, Inc. (ACRS) Q1 2026 Earnings Call
Revenue
$2.00M
▲ 37.2% YoY
Diluted EPS
$-0.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-14
Aclaris Therapeutics, Inc. (ACRS) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-01-06
Aclaris Therapeutics, Inc. (ACRS) Q4 2025 Earnings Call
Revenue
$1.29M*
▼ 85.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q1
2024-05-07
Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript
Positive tone ATI-2138 clinical positioning Atopic dermatitis market opportunity Differentiation from ritlecitinib
Revenue
$2.40M
▼ 5.1% YoY
Diluted EPS
$-0.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript
Revenue
$2.53M
▲ 74% YoY
Diluted EPS
$-0.42
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Aclaris Therapeutics, Inc. (ACRS) Q4 2019 Earnings Call
Revenue
$1.09M*
▼ 70.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–7 of 7 earnings calls
Key facts CIK 1557746 CUSIP 00461U105 13F (30d) 79 filings 79 filers Visit website Investor relations